LY3200882

Small molecule targets TGFBR1 via inhibition

Developed for: cancer · cancer of unknown primary site · colorectal cancer
Investigated by: Eli Lilly and Company · Agendia · Azienda Ospedaliera Niguarda Cà Granda · Catalan Institute of Health · European Organisation for Research and Treatment of Cancer - EORTC · Fundación para la Investigación del Hospital Clínico de Valencia
+6 more
· Merck Sharp & Dohme LLC · The Netherlands Cancer Institute · Universitaire Ziekenhuizen KU Leuven · University of Campania Luigi Vanvitelli · University of Turin, Italy · Vall d'Hebron Institute of Oncology

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT03792139	Jan → Feb 2019	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT02937272	Nov 2016 → Feb 2020 overdue	cancer	Eli Lilly and Company	Active not recruiting	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT04031872	Jan 2020	colorectal cancer	The Netherlands Cancer Institute	Withdrawn	No outcome recorded
Phase 1/2	NCT04158700	Dec 2019 → May 2023	cancer of unknown primary site	Eli Lilly and Company	Withdrawn	No outcome recorded Stop: Business

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	LY3200882	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02937272 ↗ 3 NCT04031872 ↗ NCT03792139 ↗ NCT04158700 ↗
Action	Inhibit	“small molecule inhibitor, LY3200882” PMID 34548321 ↗ Sep 2021
Modality	Small molecule	— CHEMBL4594432 ↗
Route	Oral	“Administered orally.” NCT03792139 ↗
Target	TGFBR1	“inhibitor of transforming growth factor-β (TGFβ) receptor 1” NCT04158700 ↗